Approved in the United States (26), It is the first orally administered drug that uses the fecal microbiota as a raw material. Oral. The drug, produced by Seres Therapeutics in partnership with Nestlé Health Science, could be therapeutic. instead of faecal transplant.
oathTMThe drug, approved by the FDA (Food and Drug Administration), aims to prevent recurrent infections of Clostridium difficile bacteria. This pathogen causes intestinal infection, which is manifested by diarrhea and can lead to severe dehydration, malnutrition and death.
According to studies, the involvement of C. difficile may be associated with the continued use of antibiotics that not only eliminate the pathogen, but also cause great damage to the healthy microbiota.
The treatment usually used to minimize the damage is a stool transplant. In this type of intervention, stool with a healthy microbiota is transferred to the patient receiving treatment via colonoscopy or enema.
A drug with a similar effect called Rebyota already exists on the market, but its use is anal. But these treatments may soon be replaced by oral therapy.
The drug uses live bacteria produced from the fecal matter of a healthy donor. The pharmacist processes the material, collecting beneficial bacteria and condensing them into a capsule.
According to the company, the drug is indicated for patients over the age of 18 who have already undergone antibiotic intervention. The treatment lasts for three days and the patient should take four capsules once a day.
Seres Therapeutics shows the positive result of treatment with Vowst in a post on its website.TM It has been shown to be effective against recontamination. C. difficile In 88% of cases, within 8 weeks of the first picture. Research data was also published in The New England Journal of Medicine in 2020.
The researchers’ expectation is that Vowst can replace fecal transplants and exist as a form of prevention, reducing cases and facilitating access and use. According to FDA data, between 15,000 and 30,000 people die annually in the United States from infection by the pathogen.
The forecast is for the drug to be available on the American market from June of this year.
Source: Tec Mundo
I’m Blaine Morgan, an experienced journalist and writer with over 8 years of experience in the tech industry. My expertise lies in writing about technology news and trends, covering everything from cutting-edge gadgets to emerging software developments. I’ve written for several leading publications including Gadget Onus where I am an author.
